A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).Feng Wen, Yali Shen, Tianhai Lin et al.|Journal of Clinical Oncology|2025Cited by 3